Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q4 2023 call → NOWe need answer YES/NO based on transcript. Need assess if management describes counterparties already losing something real and ongoing, and behavior reflects that. The question is nuanced. Need focus on transcript content. We need identify if any counterparty has running meter and is acting accordingly. Examples: Tyvaso DPI partner? United Therapeutics? MannKind manufactures for UT, royalty. But is UT losing something by not having MannKind? Actually UT has product, MannKind supplies. The transcript says "we are making as much as we can around the clock. Nothing slowed down there. We know we want to build up inventory as well. So between the demand and the current amount we can manufacturer, there's no slowing down where we are with Tyvaso DPI." That suggests UT is demanding supply, MannKind producing. But is UT losing money/output if MannKind doesn't deliver? Yes, UT has demand for Tyvaso DPI, MannKind is manufacturer. But management doesn't explicitly say UT is accumulating loss while waiting. They say under-forecast launch put pressure on MannKind, and they did not miss one beat to ensure supply. That is more about MannKind's effort. Other counterparties: NTM patients? Clofazimine trial? Not yet. Marketing? For Afrezza, patients? The "running meter" concept likely about counterparties losing while they don't have company's product. Does management describe that? For Afrezza, they talk about patients need mealtime insulin, but not that patients are currently losing something that only stops when Afrezza arrives. They say people don't want slow-acting insulin. But not a running meter. Need answer YES only if both halves. Let's search transcript for expressions of counterparties pressing, accepting worse terms, etc. Could be about United Therapeutics: "record production on Tyvaso cartridges." "high-speed fill finish line ... PPQ, hopefully producing much higher volumes of Tyvaso as exit Q1 going into Q2." But that's company expanding capacity. Not counterparty losing. Maybe about partnership with United Therapeutics: "we anticipate hopefully positive milestones for Tyvaso in the future" - not. Could be about insulin purchase commitment restructured to reduce cash outlay, but that's company's own. What about "we have never seen a better time... we're being chased by people" No.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...